---
title: 'Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous
  Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter,
  Multinational, Randomized, Open-label ARIVA Trial'
date: '2025-01-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39874026/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250129170949&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The overall primary patency rate during the first six months
  following endovascular intervention for PTS was higher than expected and comparable
  between patients receiving aspirin combined with rivaroxaban and those receiving
  rivaroxaban ...'
disable_comments: true
---
CONCLUSIONS: The overall primary patency rate during the first six months following endovascular intervention for PTS was higher than expected and comparable between patients receiving aspirin combined with rivaroxaban and those receiving rivaroxaban ...